tisotumab vedotin

Home
Ligands
tisotumab vedotin

GtoPdb Ligand ID: 11719

Synonyms: HuMax-TF-ADC | TF-011-MMAE | tisotumab vedotin-tftv | Tivdak®

tisotumab vedotin is an approved drug (FDA (2021))

Comment: Tisotumab vedotin is an antibody-drug conjugate (ADC) of an anti-factor 3 monoclonal antibody that is conjugated to the antineoplastic agent monomethyl auristatin E (MMAE; PubChem CID 11542188) [1]. Tisotumab vedotin causes adverse events that are associated with disrupted coagulation [4].

No information available.

No information available.

Summary of Clinical Use
Tisotumab vedotin was developed to treat solid tumours that aberrantly express F3. High expression of F3 in cervical cancer is associated with poor prognosis. The first FDA approval (via the accelerated approval pathway) of tisotumab vedotin was as a treatment for previously treated recurrent or metastatic cervical cancer, in September 2021 [5]. This was converted to full regular approval in April 2024. Click here to link to ClinicalTrials.gov's full list of tisotumab vedotin studies.

Summary of Clinical Use

Tisotumab vedotin was developed to treat solid tumours that aberrantly express F3. High expression of F3 in cervical cancer is associated with poor prognosis.
The first FDA approval (via the accelerated approval pathway) of tisotumab vedotin was as a treatment for previously treated recurrent or metastatic cervical cancer, in September 2021 [5]. This was converted to full regular approval in April 2024.
Click here to link to ClinicalTrials.gov's full list of tisotumab vedotin studies.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT02001623	Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors	Phase 1/Phase 2 Interventional	Seagen Inc.		3
NCT03438396	A Trial of Tisotumab Vedotin in Cervical Cancer	Phase 2 Interventional	Seagen Inc.		2